Search results

Skip to results

Type

Type

Last updated

Last updated

Guidance programme

Showing 1 to 9 of 9 results for cg181

  1. What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with type 1 diabetes?

    Recommendation ID CG181/4 Question What is the effectiveness of statins and/or other LDL-cholesterol-lowering treatment in people with

    Research recommendation
    Published
    9 June 2015

  2. What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can be obtained when using a complete individual patient-based outcomes meta-analysis data set compared with using published outcomes data?

    Recommendation ID CG181/2 Question What is the improvement in the cost-effectiveness metrics for statin therapy in reducing CVD that can

    Research recommendation
    Published
    9 June 2015

  3. What is the effectiveness of statin therapy in older people?

    Recommendation ID CG181/3 Question What is the effectiveness of statin therapy in older people? Any explanatory notes(if applicable)

    Research recommendation
    Published
    9 June 2015

  4. What is the effectiveness of age alone and other routinely available risk factors compared with the formal structured multifactorial risk assessment to identify people at high risk of developing CVD?

    Recommendation ID CG181/1 Question What is the effectiveness of age alone and other routinely available risk factors compared with the

    Research recommendation
    Published
    9 June 2015

  5. What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20 mg per day compared with atorvastatin 40 mg per day and atorvastatin 80 mg per day in people without established CVD?

    Recommendation ID CG181/5 Question What is the clinical effectiveness and rate of adverse events of statin therapy using atorvastatin 20

    Research recommendation
    Published
    9 June 2015

  6. Cardiovascular disease: risk assessment and reduction, including lipid modification (CG181)

    This guideline has been updated and replaced by NICE guideline NG238.

    Withdrawn guideline

  7. Statins for the prevention of cardiovascular events (TA94)

    This guidance has been updated and replaced by NICE guideline CG181.

    Withdrawn guidance

  8. Cardiovascular disease. Patient decision aid on should I take a statin?

    risk assessment and reduction, including lipid modification. NICE guideline CG181 Evidence review C statins: efficacy and adverse...

  9. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease (CG67)

    This guidance has been updated and replaced by NICE guideline CG181.

    Withdrawn guideline